Decision support for health care: the PROforma evidence base by Fox, John et al.
Conference paper
Decision support for health care:
the PROforma evidence base
John Fox PhD
Head of Laboratory
Vivek Patkar MBBS MS
Clinical Research Fellow
Richard Thomson MA
Project Manager
Advanced Computation Laboratory, London Research Institute, Cancer Research UK, London, UK
PROforma: modelling decisions
and care pathways
PROforma is a formal language for describing guide-
lines, care pathways and protocols, and for automating
clinical processes.1,2 The method is mathematically
principled and designed to be intuitive to clinicians.
The former supports reliable and sound applications;
the latter empowers clinicians to oversee the develop-
ment of clinical applications and their safe use in
practice – neither of which are typical of conventional
software. Application development tools include the
Arezzo1 system available from InferMedLtd,3 and the
Tallis system which is used at Cancer Research UK for
internal and collaborative research projects.
PROforma: the evidence base
The PROforma approach has led to several novel
technologies, and a body of evidence gained from a
range of settings shows that they could have substan-
tial clinical value.
The ﬁrst practical application of PROforma was
CAPSULE, a system for assisting general practitioners
(GPs) in prescribing for common conditions.4 Pre-
scribing is an important application for decision support
in many clinical areas because it requires clinicians to
be able to access a large amount of constantly changing
knowledge in order to stay up to date. CAPSULE took
in patient data and produced a short list of relevant
medications, together with the arguments for and
against each option. Walton et al ’s trial of the system
showed potential substantial improvements in quality
of prescribing (about 30%, P<0.001), improved re-
source use and faster decision making.
ABSTRACT
Cancer Research UK has developed PROforma, a
formal language for modelling clinical processes,
along with associated tools for creating decision
support, care planning, clinical workﬂow manage-
ment and other applications. The PROformamethod
has been evaluated in a variety of settings: in primary
health care (prescribing, referral of suspected can-
cer patients, genetic risk assessment) and in special-
ist care of patients with breast cancer, leukaemia,
HIV infection and other conditions. About nine
years of experience have been gained with PROforma
technologies. Seven trials of decision support
applications have been published or are in prep-
aration. Each of these has shown signiﬁcant positive
eﬀects on a variety of measures of quality and/or
outcomes of care. This paper reviews the evidence
base for the clinical eﬀectiveness of these PROforma
applications, and previews the CREDO project – a
multi-centre trial of a complex PROforma appli-
cation for supporting integrated breast cancer care
across primary and secondary care settings.
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Prescribing tools also have a role in cancer care.
LISA is a PROforma system for advising on dose
adjustment in the treatment of children with acute
lymphoblastic leukaemia. A ﬁrst trial of the system
showed that without decision support, clinicians
non-deliberately deviated from the trial protocol on
22.9% of occasions.5,6 With decision support this ﬁgure
dropped to zero. Of the clinicians involved, 32 out of
36 (almost 90%) said they would use LISA if it were
routinely available. (Note that the results of this LISA
trial are indicative rather than deﬁnitive since the trial
was run on retrospective cases.) LISA has now been
incorporated into InferMed’s MACRO1 clinical trial
manager, which is being prospectively evaluated in a
clinical trial led by Cancer Research UK’s Paediatric
Oncology Unit at the London Hospital.
Deﬁnitive results have been published for an im-
portant class of application designed to tailor drug
selection anddose according to virus genotypemutation
data. Complex genotype data are being increasingly
used in clinical decision making, providing a signiﬁ-
cant opportunity for computerised decision support
to handle and interpret them eﬀectively. The Retro-
Gram1 system7 is a PROforma application, developed
by InferMed for Hoﬀman la Roche, which advises on
the use of anti-retroviral therapy for HIV-positive
patients, based on HIV-1 genotype information. It is
in use by more than 250 clinicians worldwide. The
multi-centre Havana trial8 showed that availability of
genotype data, allied with RetroGram’s interpretation
of those data and prescribing advice, signiﬁcantly
improved virological outcomes in patients (by around
33%), compared with conventional management of
HIV-positive patients without genotype data.
Genetic proﬁling is becoming increasingly import-
ant in patient care generally, and could well be an
important model for the future. However, individual-
ised care in this area is diﬃcult and time-consuming
to plan, and very diﬃcult to implement. PROforma
can support both phases, as illustrated by the REACT
treatment planner,9 a system based on PROforma
concepts. REACT was ﬁrst demonstrated in the man-
agement of type 2 diabetes,10 and has been trialled
more recently in an application to assist in individual-
ised care planning in a genetic counselling setting. This
trial (as yet unpublished) has produced encouraging
results: six out of eight clinical geneticists whoused the
systemduring counsellingwere supportive of its value.
The approach adopted could be helpful in other care
planning settings such as the management of chronic
conditions and particularly in post-genomic medicine.
As genetics and genomics acquire increased clinical
signiﬁcance and clinicians face growing demands
to keep up-to-date with the science and increase their
mathematical skills, decision support and care planning
tools will become critical to achieving best standards
of practice.
The problem of assessing genetic predispositions to
cancer and other diseases further illustrates these
issues. Genes predisposing to cancer attract consider-
able medical and public concern. As more genetic
markers become available, individuals who are worried
that theymight be at risk seek guidance from their GPs
and others. We know that GPs are willing to provide
advice and support, but they often feel they do not
have the expertise to take or analyse a family history.
Further, the problem of communicating risk to patients
who have no statistical understanding is notoriously
diﬃcult. The RAGs system was developed to help GPs
take a family history, assess risk and explain risk factors
to patients.11 An application covering breast andovarian
cancer risk was implemented for collaborators in
Oxford. Trials there showed that GPs produce signiﬁ-
cantlymore accurate family trees, risk assessments and
referral decisions with customised technologies such
as RAGs than with paper and pencil or with statistical
software such as Cyrillic.12 In a comparison with stat-
istical software and paper and pencil, RAGs was chosen
as the preferred tool 91.7% of the time.
The CADMIUM imaging system used an early ver-
sion of the PROforma approach to combine conven-
tional image processing with automated interpretation
of images and diagnosis.13 CADMIUM was trialled in
a study in which radiographers with specialist training
interpreted screening mammograms both with and
without decision support. The trial was designed to
highlight whether such systems could play a role in
improving decision making in routine breast cancer
screening. The system was designed to automatically
identify microcalciﬁcations in breast tissue and inter-
pret the pattern of calciﬁcations according to whether
they were likely to indicate benign or malignant ab-
normalities. The study indicated that the system
signiﬁcantly increased the rate of correct classiﬁcations
of malignant and benign abnormalities by radiog-
raphers, while also reducing cancer misses and false
positives.
Themost recent trial of a PROforma application (as
a module of the CREDO system described in the next
section) was also in breast cancer. The study looked at
the value of decision support in the initial assessment
(‘Triple Assessment’) of women referred to special-
ist breast clinics. A collaborating breast surgeon used
PROforma to formalise national guidelines for genetic
risk assessment and for decisions about imaging (mam-
mography and ultrasound), biopsy and management.
The trial involved a random sample of 24 doctors
working as consultants or registrars in specialist breast
units with, on average, nine years’ experience. Theywere
asked to ‘manage’ ten paper cases, ﬁve with and ﬁve
without decision support, and their decisions were
compared with a consensus of best practice deﬁned by
an expert panel. Without support, decisions deviated
from the consensus standard in approximately 50% of
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cases; with support, this ﬁgure dropped to 16%. The
majority of deviations were minor, but when decision
supportwasnot available, 8.3%ofdecisionswere judged
to represent critical errors with potential for patient
harm. This ﬁgure fell to 0.8% when decision support
was provided.
To summarise, of seven studies of PROforma ap-
plications that have yielded quantitative data, all have
shown signiﬁcant positive results on a variety of
outcome measures. With the simplest assumption
that the results were equally likely to go either way,
this pattern has a chance probability of less than 0.01
(0.57=0.008).
The CREDO trial
With the exception of the RetroGram study, trials of
PROforma concepts and tools carried out to date have
been undertaken under controlled research conditions
rather than in routine clinical settings. The next planned
trial of a PROforma system will be the largest to date
and is designed to redress the balance. The CREDO
trial will focus on breast cancer care and will seek
deﬁnitive data on the value of advanced tools for
decision support, care planning and multidisciplinary
care throughout thepatient journey.CREDOisdesigned
to support seamless patient management across pri-
mary and secondary care sectors, from presentation
and diagnosis through to treatment and follow-up.
The CREDO system is based on a comprehensive
service model that maps the entire breast cancer care
pathway in a form that lends itself to computerisation.
The CREDO service model (see Figure 1) suggests
that across the whole breast cancer journey there are
over 220 services delivered by diﬀerent professionals
in secondary and primary care settings. It further
suggests that there are approximately 65 decision points
where there is potential for errors that could have a
signiﬁcant impact on treatment eﬃcacy or patient
safety. It is interesting to note that on a simple prob-
abilitymodel, if error rates are limited to 1%across the
65 decisions, only 50% of women, on average, will get
perfect care. If error rates are raised to 5%, only 3% of
women will get perfect care. Evidence from various
studies and reports, such as Vincent’s work in National
Health Service (NHS) acute hospitals,14,15 suggests
that actual rates of deviation from evidence-based
recommendations could be 10% or higher. A main
goal of the CREDO trial is to determine to what extent
a reduction in error rates is achievable in practice
through the use of decision support.
Improving the interface between
primary and secondary care
Further aims of CREDO are to improve communi-
cations between clinicians, and shared care of patients
undergoing cancer care. The 2001 joint report on
cancer care by the Commission for Healthcare Im-
provement (now theHealthcareCommission) and the
Audit Commission on cancer care16 found that cancer
care is often fragmented, and that problems arise at the
interfaces where information and responsibilities are
transferred between care sectors. Inadequate co-ordi-
nation between primary care (where initial detection,
primary risk assessment and sometimes follow-up of a
cancer occurs) and secondary care (where most of the
treatment takes place) can increase patients’ feelings of
uncertainty. One of the reasons for this is that GPs and
breast specialists have diﬀerent roles and view the
process from diﬀerent perspectives. However, from
the patient’s point of view, the entire process, fromher
ﬁrst visit to the GP through to follow-up, is a single
journey.
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Figure 1 CREDO service model
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CREDO aims to enhance shared care by acknow-
ledging the diﬀerent goals and roles of the diﬀerent
stakeholders (primary and secondary care clinicians,
nurses, patients ...) involved in a complex pathway.
The system allows them to access the same underlying
evidence-based computerised care process, but provides
diﬀerent representations of it to meet their diﬀerent
needs. For example, CREDO provides a simple and
intuitive visual family tree for GPs to facilitate familial
breast cancer risk assessment and communication
of genetic relationships (see Figure 2). Based on the
patient’s risk category (population, moderately elevated
or high risk), CREDO can also suggest appropriate
management or referral to specialists if needed.
Forwomenwithmediumandhigh risk, familyhistory
information can be passed automatically to the appro-
priate specialist in secondary care. A CREDO module
(based on REACT, see Figure 3) can then help gather
Figure 2 CREDO style of family history taking and risk assessment (based on the RAGs system developed by
Coulson et al, 200111)
Figure 3 The REACT application for planning the care of women with elevated breast cancer risk. The top
window shows a personalised plan of interventions over time; the central window shows the risk curves
associated with the plan and the arguments for and against each intervention. The bottomwindow provides
any signiﬁcant alerts or reminders associated with the plan
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further objective and subjective patient data in order
to generate risk or other graphs, together with the pros
and cons of alternative pre-emptive interventions.
CREDO is intended to support the increasingly
demanding routines and individualised care plans
(‘workﬂows’) that are required as cancer care becomes
more complex, thereby reducing the clinician’s admin-
istrative burden and facilitating good communication
between themany individuals and specialties involved
in the patient’s care.
Special emphasis is being given to automating
information exchange between hospital and primary
care settings to keep GPs informed about their patients’
treatment status, and facilitate their participation in
management and follow-up activities. There is some
evidence in the literature to suggest that follow-up in
primary care settings is acceptable to patients and
provides similar outcomes to specialist follow-up in
breast cancer,17 but the higher demands on practi-
tioners will presumably only be acceptable if these are
oﬀset by automated communication, record keeping
and other beneﬁts of computerisation.
Overall, the CREDO trial will seek to address the
following questions:
1 Can PROforma-based decision support help bring
about improved consistency, quality and safety in
clinical decision making and patient management
throughout the patient journey?
2 Can the services be oﬀered in a form that is
acceptable to and valued by clinicians?
3 Can an integrated care pathway such as CREDO
also help to manage the administrative require-
ments of complex pathways and, through auto-
mation, lead to reduced administrative load for
clinicians?
4 Can the system help improve the experience for the
cancer patient?
We have successfully constructed a prototype of a
decision support and workﬂow management system
for breast cancer in collaborationwith clinical colleagues
at Guy’s Hospital (London, UK) and Addenbrookes
Hospital (Cambridge, UK). We believe that this dem-
onstrates that it is feasible to build a system to support
clinical decision making for many of the 65 decisions
identiﬁed in the care pathways for women with (or at
risk of developing) breast cancer, and provide support
in an intuitive and clinically acceptable way. A website
for the CREDO trial is under construction but an early
demonstration version is available.18
Conclusion
This paper has summarised the evidence base for
the clinical value of guideline-based decision sup-
port applications implemented using the PROforma
method. While the majority of the evaluation studies
carried out to date (with one signiﬁcant exception)
have been undertaken in ‘laboratory’ conditions, all
have produced positive results. These have led us
to initiate the CREDO project: a multi-centre trial,
covering primary and secondary care settings, of a
complex application for supporting integrated breast
cancer care. This trial is expected to yield deﬁnitive
results on the clinical eﬀectiveness of PROforma-
based technologies and applications. Comments, sug-
gestions and questions are welcome and can be
addressed to credoinfo@acl. icnet.uk.
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